Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MATCH Treatment Subprotocol Z1G: Copanlisib in PTEN Loss Tumors
NCT06360588Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2018
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of copanlisib in malignant solid neoplasm, lymphoma, multiple myeloma (MM), sponsored by National Cancer Institute. Started Oct 2018; status: active, not recruiting.
02
Drugs
copanlisib
03
Conditions
malignant solid neoplasmlymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT06360588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06360588.